LC-Plasma-based Vaccine Research Selected for SCARDA Project
- Towards the Development of a Vaccine to prevent Respiratory Virus Infection -
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507111790/en/
● |
Information on the |
Title: Development of an intranasal Lactococcus lactis strain Plasma vaccine inducing innate memory |
|
Representative: |
|
Representative: |
|
● |
Unique point
|
Backgrounds
SCARDA was established at AMED in March, 2022, based on the national strategy, to strengthen strategic research funding and to promote the formation of world-class research and development centers (https://www.amed.go.jp/en/program/list/21/index.html). SCARDA is supporting Research & Development for new generation vaccines. Traditional vaccines are expected to induce adaptive immune responses including antibody and T cell responses to prevent infection with pathogens such as viruses and bacteria. Recently, the concept of trained immunity has been discussed and there have been several attempts to develop vaccines inducing effective innate responses against infectious diseases, which has not yet been achieved.
LC-Plasma is characterized by its ability to activate plasmacytoid dendritic cells (pDCs) and stimulate interferon production, leading to enhancement of innate immune responses. Through joint research with NIID,
About
Under theKirin Group Vision 2027 (KV 2027), a long-term management plan launched in 2019, the Kirin Group aims to become A global leader in CSV*, creating value across our world of Food & Beverages to Pharmaceuticals. Going forward, the Kirin Group will continue to leverage its strengths to create both social and economic value through its businesses, with the aim of achieving sustainable growth in corporate value.
* Creating Shared Value. Combined added value for consumers as well as for society at large.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240507111790/en/
Press Contact
+81-3-6837-7028
https://www.kirinholdings.com/en/
kirin-cc@kirin.co.jp
1-23-1 Toyama, Shinjuku-ku,
+81-3-5285-1111
info@nih.go.jp
Source: